Application of polysaccharide microarray technology for the serodiagnosis of Burkholderia pseudomallei infection (melioidosis) in humans

Narayanan Parthasarathy; David DeShazer; Sharon J. Peacock; Vanaporn Wuthiekanun; Marilyn J. England; Sarah L. Norris; David M. Waag

doi:10.1080/07328300802030761

Application of polysaccharide microarray technology for the serodiagnosis of Burkholderia pseudomallei infection (melioidosis) in humans

Narayanan Parthasarathy^*
, David DeShazer
, Sharon J. Peacock
, Vanaporn Wuthiekanun
, Marilyn J. England
, Sarah L. Norris
, David M. Waag

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Burkholderia pseudomallei is the causative agent of melioidosis, a bacterial infection endemic in tropical regions including southeast Asia and northern Australia. B. pseudomallei contains structurally unique polysaccharides (capsular polysaccharide and O-antigen saccharides of lipopolysaccharide). A polysaccharide microarray platform was developed by immobilizing these polysaccharides onto glass slides. Employing this microarray, we were able to demonstrate the presence of antibodies to these polysaccharide antigens in the sera of melioidosis patients, but not in serum from nonmelioidosis human subjects. The advantages of this polysaccharide microarray technology over the conventional tests for the serodiagnosis of melioidosis are discussed.

Original language	English
Pages (from-to)	32-40
Number of pages	9
Journal	Journal of Carbohydrate Chemistry
Volume	27
Issue number	1
DOIs	https://doi.org/10.1080/07328300802030761
Publication status	Published - Jan 2008
Externally published	Yes

Bibliographical note

Funding Information:
The research described herein was sponsored by the U.S. Army Medical Research and Materiel Command under projects 06-4-2P-004 and AP-06-035. The use of human serum samples was approved by Human Use Committee (FY 06-36, HP-06-36). Opinions, interpretations, conclusions, and recommendations are those of the authors and not endorsed by the U.S. Army. The support of staff at Sappasithiprasong Hospital, Ubon Ratchathani, and the Mahidol Oxford Tropical Medicine Research Unit, particularly Dr. Direk Lim-mathurotsakul and Dr. Allen Cheng, is gratefully acknowledged. SP is funded by a Wellcome Trust Career Development Fellowship in Clinical Tropical Medicine.

Keywords

Burkholderia pseudomallei
Melioidosis
Polysaccharide microarray
Serodiagnosis

Access to Document

10.1080/07328300802030761

Cite this

@article{5d598c95e9e44345bd47055f7c35445f,

title = "Application of polysaccharide microarray technology for the serodiagnosis of Burkholderia pseudomallei infection (melioidosis) in humans",

abstract = "Burkholderia pseudomallei is the causative agent of melioidosis, a bacterial infection endemic in tropical regions including southeast Asia and northern Australia. B. pseudomallei contains structurally unique polysaccharides (capsular polysaccharide and O-antigen saccharides of lipopolysaccharide). A polysaccharide microarray platform was developed by immobilizing these polysaccharides onto glass slides. Employing this microarray, we were able to demonstrate the presence of antibodies to these polysaccharide antigens in the sera of melioidosis patients, but not in serum from nonmelioidosis human subjects. The advantages of this polysaccharide microarray technology over the conventional tests for the serodiagnosis of melioidosis are discussed.",

keywords = "Burkholderia pseudomallei, Melioidosis, Polysaccharide microarray, Serodiagnosis",

author = "Narayanan Parthasarathy and David DeShazer and Peacock, \{Sharon J.\} and Vanaporn Wuthiekanun and England, \{Marilyn J.\} and Norris, \{Sarah L.\} and Waag, \{David M.\}",

note = "Funding Information: The research described herein was sponsored by the U.S. Army Medical Research and Materiel Command under projects 06-4-2P-004 and AP-06-035. The use of human serum samples was approved by Human Use Committee (FY 06-36, HP-06-36). Opinions, interpretations, conclusions, and recommendations are those of the authors and not endorsed by the U.S. Army. The support of staff at Sappasithiprasong Hospital, Ubon Ratchathani, and the Mahidol Oxford Tropical Medicine Research Unit, particularly Dr. Direk Lim-mathurotsakul and Dr. Allen Cheng, is gratefully acknowledged. SP is funded by a Wellcome Trust Career Development Fellowship in Clinical Tropical Medicine.",

year = "2008",

month = jan,

doi = "10.1080/07328300802030761",

language = "English",

volume = "27",

pages = "32--40",

journal = "Journal of Carbohydrate Chemistry",

issn = "0732-8303",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Application of polysaccharide microarray technology for the serodiagnosis of Burkholderia pseudomallei infection (melioidosis) in humans

AU - Parthasarathy, Narayanan

AU - DeShazer, David

AU - Peacock, Sharon J.

AU - Wuthiekanun, Vanaporn

AU - England, Marilyn J.

AU - Norris, Sarah L.

AU - Waag, David M.

N1 - Funding Information: The research described herein was sponsored by the U.S. Army Medical Research and Materiel Command under projects 06-4-2P-004 and AP-06-035. The use of human serum samples was approved by Human Use Committee (FY 06-36, HP-06-36). Opinions, interpretations, conclusions, and recommendations are those of the authors and not endorsed by the U.S. Army. The support of staff at Sappasithiprasong Hospital, Ubon Ratchathani, and the Mahidol Oxford Tropical Medicine Research Unit, particularly Dr. Direk Lim-mathurotsakul and Dr. Allen Cheng, is gratefully acknowledged. SP is funded by a Wellcome Trust Career Development Fellowship in Clinical Tropical Medicine.

PY - 2008/1

Y1 - 2008/1

N2 - Burkholderia pseudomallei is the causative agent of melioidosis, a bacterial infection endemic in tropical regions including southeast Asia and northern Australia. B. pseudomallei contains structurally unique polysaccharides (capsular polysaccharide and O-antigen saccharides of lipopolysaccharide). A polysaccharide microarray platform was developed by immobilizing these polysaccharides onto glass slides. Employing this microarray, we were able to demonstrate the presence of antibodies to these polysaccharide antigens in the sera of melioidosis patients, but not in serum from nonmelioidosis human subjects. The advantages of this polysaccharide microarray technology over the conventional tests for the serodiagnosis of melioidosis are discussed.

AB - Burkholderia pseudomallei is the causative agent of melioidosis, a bacterial infection endemic in tropical regions including southeast Asia and northern Australia. B. pseudomallei contains structurally unique polysaccharides (capsular polysaccharide and O-antigen saccharides of lipopolysaccharide). A polysaccharide microarray platform was developed by immobilizing these polysaccharides onto glass slides. Employing this microarray, we were able to demonstrate the presence of antibodies to these polysaccharide antigens in the sera of melioidosis patients, but not in serum from nonmelioidosis human subjects. The advantages of this polysaccharide microarray technology over the conventional tests for the serodiagnosis of melioidosis are discussed.

KW - Burkholderia pseudomallei

KW - Melioidosis

KW - Polysaccharide microarray

KW - Serodiagnosis

UR - https://www.scopus.com/pages/publications/45949089731

U2 - 10.1080/07328300802030761

DO - 10.1080/07328300802030761

M3 - Article

AN - SCOPUS:45949089731

SN - 0732-8303

VL - 27

SP - 32

EP - 40

JO - Journal of Carbohydrate Chemistry

JF - Journal of Carbohydrate Chemistry

IS - 1

ER -

Application of polysaccharide microarray technology for the serodiagnosis of Burkholderia pseudomallei infection (melioidosis) in humans

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this